
PFF Clinical Trial Innovation (CTI) Webinar Series June 2025
The PFF hosted a webinar as part of the PFF CTI Webinar Series on Wednesday, June 4, 2025. You can now watch the recording to hear from people leading trials in pulmonary fibrosis (PF) and interstitial lung disease (ILD) and learn more about studies that are currently recruiting or that have new data to share.
🔹 Vicore Pharma AB
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis (ASPIRE)
James Nolin, PhD; Senior Clinical Science Liaison at Vicore Pharma AB
🔹 Boehringer Ingelheim
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Thomas Porter, MBA, MPH; Director, Clinical Development Lead at Boehringer Ingelheim
🔹 Pulmonary Fibrosis Foundation
PFF Community Registry
Jessica Shore, PhD, RN; Senior Vice President, Clinical Affairs and Quality at PFF
DISCLAIMER: Participation in the CTI Webinar Series and references to specific commercial entities (companies) or products do not reflect endorsement by the PFF. The PFF does not endorse or promote any products or services participants discuss in the CTI Webinar Series, and participants cannot suggest otherwise. Please note that any information contained in this presentation is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice. Always consult your personal physician or health care provider to determine if a clinical trial is right for you.